CL2024001071A1 - Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1. - Google Patents

Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1.

Info

Publication number
CL2024001071A1
CL2024001071A1 CL2024001071A CL2024001071A CL2024001071A1 CL 2024001071 A1 CL2024001071 A1 CL 2024001071A1 CL 2024001071 A CL2024001071 A CL 2024001071A CL 2024001071 A CL2024001071 A CL 2024001071A CL 2024001071 A1 CL2024001071 A1 CL 2024001071A1
Authority
CL
Chile
Prior art keywords
methods
effecting
administering
npr1
hemodynamic change
Prior art date
Application number
CL2024001071A
Other languages
English (en)
Spanish (es)
Inventor
Dunn Michael
Kithcart Aaron
Adam Olenchock Benjamin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2024001071A1 publication Critical patent/CL2024001071A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024001071A 2021-10-11 2024-04-10 Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1. CL2024001071A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163254447P 2021-10-11 2021-10-11

Publications (1)

Publication Number Publication Date
CL2024001071A1 true CL2024001071A1 (es) 2024-12-06

Family

ID=84045029

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001071A CL2024001071A1 (es) 2021-10-11 2024-04-10 Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1.

Country Status (12)

Country Link
US (2) US20240327539A1 (enExample)
EP (1) EP4415820A1 (enExample)
JP (1) JP2024537284A (enExample)
KR (1) KR20240099275A (enExample)
CN (1) CN118159290A (enExample)
AU (1) AU2022363841A1 (enExample)
CA (1) CA3234238A1 (enExample)
CL (1) CL2024001071A1 (enExample)
CO (1) CO2024005662A2 (enExample)
IL (1) IL311917A (enExample)
MX (1) MX2024004302A (enExample)
WO (1) WO2023064769A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023107957A1 (en) 2021-12-06 2023-06-15 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof
AU2024287056A1 (en) * 2023-06-08 2025-12-11 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-npr1 antibody and pharmaceutical use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
EP2370098A4 (en) 2008-12-03 2013-07-17 Morphosys Ag Antibodies for guanylyl cyclase receptors
CA3115102A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Anti-npr1 antibodies and uses thereof
PH12021553101A1 (en) * 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
US12325752B2 (en) * 2020-12-18 2025-06-10 Regeneron Pharmaceuticals, Inc. Immunoglobulin proteins that bind to NPR1 agonists

Also Published As

Publication number Publication date
JP2024537284A (ja) 2024-10-10
CA3234238A1 (en) 2023-04-20
IL311917A (en) 2024-06-01
MX2024004302A (es) 2024-06-19
WO2023064769A1 (en) 2023-04-20
KR20240099275A (ko) 2024-06-28
CO2024005662A2 (es) 2024-05-10
AU2022363841A1 (en) 2024-03-28
US20240327539A1 (en) 2024-10-03
EP4415820A1 (en) 2024-08-21
US20250034279A1 (en) 2025-01-30
CN118159290A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
CO2024005662A2 (es) Métodos para efectuar un cambio hemodinámico administrando un anticuerpo anti-npr1
CL2023002682A1 (es) Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
MX2022004678A (es) Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
DOP2021000148A (es) Compuestos moduladores de fxr (nr1h4)
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
CL2021003272A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
PE20220337A1 (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
CL2023003124A1 (es) Anticuerpos anti-tslp modificados
ES3064117T3 (en) Methods for enhancing adoptive cell transfer immunotherapies
CL2025003126A1 (es) Anticuerpo biespecífico de cadena pesada anti-cd3 y anti-receptor de folato alfa (folr1).
CL2024002623A1 (es) Formas solidas, sales y procesos de preparacion de un inhibidor de cdk2.
MX2023009882A (es) Anticuerpos anti-muc1-c y estructuras car-t.
AR116141A1 (es) CATALIZADOR QUE CONTIENE Ni PARA LA OLIGOMERIZACIÓN DE OLEFINAS
MX2020011529A (es) Un metodo para optimizar la expresion de anticuerpos.
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
CO2022006014A2 (es) Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas
ECSP21082195A (es) Formas sólidas de un inhibidor de glyt1
CO2025003362A2 (es) Conjugados de fármacos anticuerpo anti-sez6
CO2021017343A2 (es) Formas de sales cristalinas de un inhibidor de cinasas
CL2024003600A1 (es) Composiciones de arn para la administración de antígenos de viruela símica y métodos relacionados
CL2025000292A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos
MX2022002941A (es) Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.
CO2024003094A2 (es) Compuesto imidazocíclico y aplicación del mismo
PE20221009A1 (es) Sintesis de un inhibidor de calicreina plasmatica a escala de proceso